Kalvista Total Liab vs Retained Earnings Analysis
KALV Stock | USD 12.04 0.45 3.60% |
Kalvista Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kalvista Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kalvista Pharmaceuticals is a good investment. Please check the relationship between Kalvista Pharmaceuticals Total Liab and its Retained Earnings accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.
Total Liab vs Retained Earnings
Total Liab vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kalvista Pharmaceuticals Total Liab account and Retained Earnings. At this time, the significance of the direction appears to have very week relationship.
The correlation between Kalvista Pharmaceuticals' Total Liab and Retained Earnings is 0.21. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Kalvista Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kalvista Pharmaceuticals' Total Liab and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Kalvista Pharmaceuticals are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Liab i.e., Kalvista Pharmaceuticals' Total Liab and Retained Earnings go up and down completely randomly.
Correlation Coefficient | 0.21 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Kalvista Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kalvista Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.Issuance Of Capital Stock is likely to climb to about 58.6 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.6 M in 2024.
2023 | 2024 (projected) | Net Interest Income | 2.6M | 2.7M | Non Recurring | 1.3M | 1.2M |
Kalvista Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Kalvista Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kalvista Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 118.1M | 92.5M | 272.0M | 203.9M | 183.2M | 88.7M | |
Short Long Term Debt Total | 54K | 1.6M | 5.9M | 8.2M | 8.2M | 4.6M | |
Other Current Liab | 5.5M | 6.9M | 7.0M | 9.1M | 29K | 27.6K | |
Total Current Liabilities | 18.1M | 7.7M | 9.8M | 11.6M | 15.0M | 4.1M | |
Total Stockholder Equity | 96.7M | 83.8M | 257.2M | 185.1M | 161.0M | 66.4M | |
Property Plant And Equipment Net | 3.7M | 7.5M | 10.0M | 10.8M | 12.4M | 13.0M | |
Net Debt | (14.1M) | (44.7M) | (22.5M) | (48.0M) | (43.2M) | (41.0M) | |
Retained Earnings | (92.5M) | (121.6M) | (167.8M) | (250.2M) | (343.1M) | (76.3M) | |
Accounts Payable | 2.9M | 1.7M | 2.0M | 3.6M | 4.8M | 2.0M | |
Cash | 32.0M | 15.8M | 50.6M | 30.7M | 56.2M | 32.8M | |
Non Current Assets Total | 3.8M | 7.7M | 10.2M | 10.9M | 12.5M | 13.1M | |
Cash And Short Term Investments | 100.8M | 67.7M | 248.9M | 166.2M | 149.4M | 77.5M | |
Common Stock Total Equity | 17K | 18K | 24K | 25K | 34K | 18.2K | |
Common Stock Shares Outstanding | 17.7M | 19.1M | 24.5M | 27.9M | 32.1M | 33.7M | |
Liabilities And Stockholders Equity | 92.5M | 272.0M | 203.9M | 183.2M | 210.7M | 221.2M | |
Non Current Liabilities Total | 1.1M | 5.0M | 7.2M | 7.1M | 6.4M | 11.2M | |
Other Current Assets | 4.5M | 4.9M | 10.6M | 6.4M | 1.0M | 959.5K | |
Other Stockholder Equity | 207.2M | 426.4M | 439.1M | 507.1M | (75K) | (71.3K) | |
Total Liab | 21.4M | 8.8M | 14.8M | 18.8M | 22.2M | 7.1M | |
Property Plant And Equipment Gross | 2.4M | 3.7M | 7.5M | 10.0M | 10.8M | 764.8K | |
Total Current Assets | 115.5M | 88.7M | 264.3M | 193.6M | 172.3M | 85.2M | |
Accumulated Other Comprehensive Income | (1.9M) | (1.9M) | (1.4M) | (3.9M) | (3.1M) | (659.4K) | |
Short Term Debt | 54K | 588K | 863K | 977K | 1.1M | 1.2M | |
Common Stock | 17K | 18K | 24K | 25K | 34K | 15.9K | |
Capital Surpluse | 191.1M | 207.2M | 426.4M | 439.1M | 507.1M | 115.8M | |
Property Plant Equipment | 2.4M | 2.0M | 1.8M | 2.2M | 2.9M | 1.3M | |
Net Tangible Assets | 83.8M | 257.2M | 185.1M | 161.0M | 43.1M | 40.9M | |
Net Receivables | 11.3M | 16.5M | 10.4M | 14.1M | 16.6M | 2.1M | |
Retained Earnings Total Equity | (71.7M) | (92.5M) | (121.6M) | (167.8M) | (250.2M) | (343.1M) | |
Net Invested Capital | 83.8M | 257.2M | 185.1M | 161.0M | 185.2M | 132.4M | |
Net Working Capital | 81.0M | 254.5M | 182.1M | 157.3M | 180.9M | 132.0M | |
Capital Lease Obligations | 1.6M | 5.9M | 8.2M | 8.2M | 9.5M | 9.9M | |
Capital Stock | 18K | 24K | 25K | 34K | 39.1K | 26.0K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kalvista Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kalvista Pharmaceuticals' short interest history, or implied volatility extrapolated from Kalvista Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Kalvista Stock analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Kalvista Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kalvista Pharmaceuticals. If investors know Kalvista will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kalvista Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.214 | Quarterly Revenue Growth 0.307 | Return On Assets (0.42) | Return On Equity (0.79) |
The market value of Kalvista Pharmaceuticals is measured differently than its book value, which is the value of Kalvista that is recorded on the company's balance sheet. Investors also form their own opinion of Kalvista Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kalvista Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kalvista Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kalvista Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kalvista Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kalvista Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kalvista Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.